Cost cut needed to cover Friedreich's Ataxia drug - NCPE
There would have to be "significant price reduction" in the cost of a drug to treat Friedreich's Ataxia for it to be covered by the HSE, according to the National Centre for Pharmacoeconomics (NCPE).
The cost of a drug to treat Friedreich's Ataxia must be significantly reduced for the HSE to cover it, according to the National Centre for Pharmacoeconomics (NCPE). Clinical Director Professor Michael Barry highlighted how other services could be affected if the projected €160 million expenditure on Skyclarys were to be made. The HSE's Drugs Group decided not to recommend coverage for Skyclarys, a drug for the rare neurological disease that damages the spinal cord, peripheral nerves, and part of the brain.
The NCPE found the drug's pricing by Biogen to be non-cost effective. Despite the NCPE's recommendation against the HSE providing Skyclarys, campaigners continue to lobby for its approval.
Written by urgent.news from RTE News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
